The latest policy and advocacy updates related to the field of clinical and translational science.
Congress spent the month of October in recess, with Representatives and Senators on the campaign trail ahead of the November elections. One of the last actions by Congress was to pass a Continuing Resolution to keep federal agencies operating at their current level until December 16th so legislators can continue to work to finalize the Fiscal Year (FY) 2023 spending bills by the end of the year. Presently, Congress plans to use the Lame Duck session following the election to finalize FY 2023 appropriations and to pass any critical outstanding bills. The results of the election will have some bearing on how Congress finalizes the annual spending bills and the allocations for key programs, even if the new Congress will not adjourn until January of next year.
One of the key items left to be resolved through the end of the year appropriations process is the authorizing legislation and funding provisions for the Advanced Research Projects Agency for Health (ARPA-H). The House and Senate currently have differing funding levels as well as divergent authorizing legislation, but persistent issues are expected to be resolved in a timely fashion. Moreover, the initial funding provided by Congress for ARPA-H in FY 2022 is already being used to establish the agency, identify its leadership, and stand-up grant making and related activities without delay.
For the remainder of the year, CCTS encourages advocates to reach out to congressional contacts and encourage support the community’s annual funding recommendations (listed below). There will be ample opportunity to educate new members during the next Congress, but for now there is a tangible opportunity to secure pending FY 2023 funding.